Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Diluted EPS of $4.79 per share (loss) for fiscal year 2024.
LIPELLA PHARMACEUTICALS INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$4.79 | +22.2% |
| 2023 | -$6.16 | -862.5% |
| 2022 | -$0.64 | -16.4% |
| 2021 | -$0.55 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.28 | +78.3% | +9.7% |
| June 30, 2025 | -$0.31 | +68.7% | +51.6% |
| March 31, 2025 | -$0.64 | +51.1% | +50.4% |
| September 30, 2024 | -$1.29 | +29.9% | -30.3% |
| June 30, 2024 | -$0.99 | -266.7% | +24.4% |
| March 31, 2024 | -$1.31 | -589.5% | +28.8% |
| September 30, 2023 | -$1.84 | -982.4% | -581.5% |
| June 30, 2023 | -$0.27 | -35.0% | -42.1% |
- LIPELLA PHARMACEUTICALS INC. showed an increase of +22.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, LIPELLA PHARMACEUTICALS INC.’s diluted eps has declined by 770.9% (from $0.55 per share (loss) to $4.79 per share (loss)).
- The most recent figure is from LIPELLA PHARMACEUTICALS INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: